comparemela.com

Jnj Revenue News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Is Johnson & Johnson Stock A Better Pick Over AbbVie?

AbbVie trades at a higher valuation of 5.5x trailing revenues, compared to 4.6x for JNJ.

Health careTrefis high quality portfolioAbbvie revenue comparisonWhat droveNet income changeJohnson amp stocka better pickJohnson ampJnj stockJnj revenueAbbv stockAbbv revenue

Should You Pick Johnson & Johnson Stock At $160?

Johnson & Johnson (NYSE: JNJ) reported its Q4 results last month, with revenues and earnings marginally above the street estimates.

Health careTrefis high quality portfolioInnovative medicineJohnson amp stockJohnson ampS ampp 500Jnj stockJnj revenueJnj valuationJnj q4

Should You Pick Johnson & Johnson Stock After A 6% Fall In A Month Despite Upbeat Q3?

Johnson & Johnson (NYSE: JNJ) reported its Q3 results last week, with revenues and earnings beating the street estimates.

Health careTrefis high quality portfolioInnovative medicineS ampp 500Hq portfolioJnj stockJnj revenueJohnson ampJnj valuationJnj q3

What s Happening With Johnson & Johnson Stock?

Johnson & Johnson stock (NYSE: JNJ) has seen a 3% fall in a month, compared to a 2% fall for the broader S&P500 index.

Johnson imbruvicaJohnson medtechSharpe ratioTrefis reinforced valueWhy johnsonJohnson stock movedJohnson peersS ampp 500 indexJnj stockJnj revenueBig pharmaJohnson amp

Johnson & Johnson Poised For A Muted Q2?

We expect the company’s revenues to come in at $24.6 billion, marginally below the consensus estimate of $24.7 billion.

Johnson earnings previewConsumer healthcareJohnson peersJohnson ampJnj stockJnj revenueJ ampJnj q2Jnj valuation

vimarsana © 2020. All Rights Reserved.